Holen Sie sich die Stockscreener-App
4.67
1.52%
0.07
Handel nachbörslich:
4.74
0.07
+1.50%
Schlusskurs vom Vortag:
$4.60
Offen:
$4.53
24-Stunden-Volumen:
2.24M
Relative Volume:
2.39
Marktkapitalisierung:
$388.52M
Einnahmen:
$14.20M
Nettoeinkommen (Verlust:
$-49.59M
KGV:
-5.5437
EPS:
-0.8424
Netto-Cashflow:
$-35.25M
1W Leistung:
+26.56%
1M Leistung:
+25.88%
6M Leistung:
+2.19%
1J Leistung:
+264.84%
1-Tages-Spanne:
$4.40
$4.80
1-Wochen-Bereich:
$3.511
$4.83
52-Wochen-Spanne:
$1.24
$5.81
Opus Genetics Inc Stock (IRD) Company Profile
Firmenname
Opus Genetics Inc
Sektor
Branche
Telefon
248-681-9815
Adresse
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
4.67 | 342.77M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-03-16 | Eingeleitet | Oppenheimer | Outperform |
| 2026-01-20 | Eingeleitet | BTIG Research | Buy |
| 2025-12-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-11-25 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-29 | Eingeleitet | Wedbush | Outperform |
| 2025-10-16 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-04-11 | Eingeleitet | Craig Hallum | Buy |
| 2024-11-13 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Opus Genetics Inc Aktie (IRD) Neueste Nachrichten
Balyasny Asset Management L.P. Expands Opus Genetics Inc (IRD) S - GuruFocus
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Opus Genetics stock maintains buy rating ahead of trial data By Investing.com - Investing.com Canada
Citizens reiterates Opus Genetics stock rating ahead of trial data - Investing.com
Citizens reiterates Opus Genetics stock rating ahead of trial data By Investing.com - Investing.com India
Wall Street Zen Upgrades Opus Genetics (NASDAQ:IRD) to "Hold" - MarketBeat
IRD Q2 2026 Earnings: Narrower-than-Expected Loss of -$0.14 Beats Estimates, Though Shares Slip 2.96%Profitability Analysis - vinanet.vn
Opus Genetics (NASDAQ:IRD) Rating Increased to Hold at Zacks Research - MarketBeat
Opus Genetics Q3 EPS Lifted by Brookline Capital Markets - MarketBeat
Brokers Set Expectations for Opus Genetics FY2030 Earnings - MarketBeat
Opus Genetics FY2026 EPS Estimate Boosted by HC Wainwright - MarketBeat
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How FDA Alignment Is Shaping Opus Genetics' OPGx-LCA5 Development Strategy - Clinical Leader
Opus Genetics completes phase 3 enrollment for OPGx-LCA5 gene therapy - Glance by Eyes On Eyecare
Opus Genetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Opus Genetics Inc (IRD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Opus Genetics (IRD) Gets a Buy from RBC Capital - The Globe and Mail
Piper Sandler Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Is Opus Genetics Inc (IRD) Significantly Overvalued After Q2 Ear - GuruFocus
Opus Genetics (IRD) Q1 2026 Earnings: Deep EPS Miss Heightens Scrutiny on Clinical-Stage SpendingRevenue Beat Analysis - vinanet.vn
OPUS GENETICSMAY OFFER AND SELL UP TO $300 MLN OF SECURITIESSEC FILING - Moomoo
Opus Genetics (NASDAQ:IRD) Upgraded at Wall Street Zen - MarketBeat
IRD Maintained by RBC Capital -- Price Target Lowered to $9.00 - GuruFocus
A. G. P. Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $9 - Moomoo
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $9 to $10 - Moomoo
Opus GeneticsMay Offer And Sell Up To $300 Million Of SecuritiesSEC Filing - TradingView
RBC Adjusts PT on Opus Genetics to $9 From $10, Maintains Outperform Speculative Risk Rating - marketscreener.com
Opus Genetics (NASDAQ: IRD) sets $300M shelf and $125M ATM stock plan - Stock Titan
Opus Genetics earnings beat by $0.02, revenue fell short of estimates - Investing.com Canada
Opus Genetics (NASDAQ:IRD) Releases Earnings Results - MarketBeat
Opus Genetics, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.14) — 10-Q Summary - TradingView
Opus Genetics (Nasdaq: IRD) hit by $73.6M loss, rising warrant costs - Stock Titan
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update - The Manila Times
Opus Genetics Q2 revenue falls and misses estimates - TradingView
IRD: Gene therapy pipeline advances with strong cash position and key clinical milestones ahead - TradingView
Opus Genetics Reports Q2 2026 Results and Advances Multiple IRD Gene Therapy Programs with OPGx-BEST1 Data Expected in September - Quiver Quantitative
Opus Genetics reports Q2 2026 results: $0.8M revenue, $8.1M net loss, $88.8M cash - TradingView
Opus Genetics Completes Phase 3 Enrollment for AAV Gene Therapy OPGx-LCA5 - BioPharm International
Opus Genetics (IRD) to Release Quarterly Earnings on Wednesday - MarketBeat
BTIG Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Opus Genetics completes enrollment in LCA5 gene therapy trial - Investing.com
Opus Genetics completes enrollment in LCA5 gene therapy trial By Investing.com - Investing.com South Africa
Opus Genetics Completes Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 For LCA5-Associated Inherited Retinal Disease - marketscreener.com
Opus Genetics, Inc. $IRD Shares Sold by Perceptive Advisors LLC - MarketBeat
Opus Genetics, Inc. Revenue Breakdown – NASDAQ:IRD - TradingView
Opus Genetics (IRD) Slides 3.4% to $3.71 as Gene Therapy Stock Presses Key SupportIV Contraction - vinanet.vn
Opus Genetics (IRDC) Q1 2026 Earnings: Wide EPS Miss Reflects Pre-Revenue R&D InvestmentPre-Announcement Alert - vinanet.vn
Opus Genetics, Inc. Revenue Breakdown – FWB:R3X1 - TradingView
Form 4 Opus Genetics Inc For: 27 July By Investing.com - Investing.com India
Opus Genetics Inc (IRD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Finanzdaten der Opus Genetics Inc-Aktie (IRD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Opus Genetics Inc-Aktie (IRD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| YERXA BENJAMIN R | President |
Jul 23 '26 |
Sale |
2.97 |
7,429 |
22,064 |
704,106 |
| SCHACHLE JOSEPH K | Chief Operating Officer |
Jul 23 '26 |
Sale |
2.94 |
4,644 |
13,653 |
291,440 |
| Magrath George | Chief Executive Officer |
Jul 23 '26 |
Sale |
2.95 |
9,475 |
27,926 |
1,731,869 |
| Gagnon Robert E. | Chief Financial Officer |
Jul 23 '26 |
Sale |
2.95 |
7,783 |
22,942 |
584,375 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):